hu14.18-interleukin-2 fusion protein
(… in-ter-LOO-kin-2 FYOO-zhun PROH-teen)
An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.